Amycretin
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Subcutaneous amycretin phase 1b/2a study
Once-weekly escalation from 0.3 mg; different groups reached 1.25, 5, 20 or 60 mg
20, 28 or 36 weeks depending on the study group
Dahl et al., Lancet (2025) ↗When results may show
- When change was measured
- Weight endpoints were group-specific: weeks 20, 28 and 36. Many participants discontinued; estimates depend on the analysis.
- When to assess
- 20, 28 or 36 weeks depending on the study group
- Conditions and limitations
- 125 adults aged 18–55 with overweight or obesity. The oral and injected forms are different study products. The targets are not one recommended escalation sequence, and missing intermediate steps are not supplied.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Dahl et al., Lancet (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Amycretin describe 5–20 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Dahl et al., Lancet (2025)The oral and injected forms are different study products. The targets are not one recommended escalation sequence, and missing intermediate steps are not supplied.
Next steps
Amycretin beginner guideOpen Amycretin planning worksheetEstimate Amycretin vial costTrack Amycretin notes